As of 2025-03-17, the Relative Valuation of Avidity Biosciences Inc (RNA) is (101.48) USD. This relative valuation is based on P/E multiples. With the latest stock price at 31.11 USD, the upside of Avidity Biosciences Inc based on Relative Valuation is -426.2%.
The range of the Relative Valuation is (83.97) - (102.90) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 31.3x - 47.6x | 41.2x |
| Forward P/E multiples | 26.9x - 38.4x | 34.5x |
| Fair Price | (83.97) - (102.90) | (101.48) |
| Upside | -369.9% - -430.8% | -426.2% |
| Date | P/E |
| 2025-03-07 | -11.20 |
| 2025-03-06 | -11.32 |
| 2025-03-05 | -11.02 |
| 2025-03-04 | -10.65 |
| 2025-03-03 | -10.90 |
| 2025-02-28 | -11.43 |
| 2025-02-27 | -10.85 |
| 2025-02-26 | -11.06 |
| 2025-02-25 | -10.88 |
| 2025-02-24 | -11.39 |
| 2025-02-21 | -11.61 |
| 2025-02-20 | -12.13 |
| 2025-02-19 | -11.90 |
| 2025-02-18 | -11.94 |
| 2025-02-14 | -12.05 |
| 2025-02-13 | -12.32 |
| 2025-02-12 | -11.87 |
| 2025-02-11 | -12.60 |
| 2025-02-10 | -12.80 |
| 2025-02-07 | -13.02 |
| 2025-02-06 | -13.10 |
| 2025-02-05 | -12.93 |
| 2025-02-04 | -12.43 |
| 2025-02-03 | -11.92 |
| 2025-01-31 | -12.28 |
| 2025-01-30 | -12.17 |
| 2025-01-29 | -11.91 |
| 2025-01-28 | -11.96 |
| 2025-01-27 | -11.35 |
| 2025-01-24 | -11.07 |
| 2025-01-23 | -11.24 |
| 2025-01-22 | -11.22 |
| 2025-01-21 | -11.50 |
| 2025-01-17 | -10.79 |
| 2025-01-16 | -10.55 |
| 2025-01-15 | -10.39 |
| 2025-01-14 | -10.09 |
| 2025-01-13 | -10.60 |
| 2025-01-10 | -10.99 |
| 2025-01-08 | -11.16 |
| 2025-01-07 | -11.48 |
| 2025-01-06 | -11.72 |
| 2025-01-03 | -11.38 |
| 2025-01-02 | -11.63 |
| 2024-12-31 | -10.85 |
| 2024-12-30 | -10.88 |
| 2024-12-27 | -11.23 |
| 2024-12-26 | -11.61 |
| 2024-12-24 | -11.69 |
| 2024-12-23 | -11.80 |